Otonomy Gets $49M In New Funding

San Diego-based biopharmaceuticals developer Otonomy--which is developing treatments for inner and middle ear disorders--has roped in a big, $49M funding, the company announced this morning. The Series D funding came from Jennison Associates LLC, Perceptive Advisors, Federated Kaufmann Funds, Clough Capital Partners LP, Ally Bridge Group, as well as existing investors OrbiMed Advisors LLC, Novo Ventures, TPG Biotech, Avalon Ventures, Domain Associates, RiverVest Venture Partners, Aperture Venture Partners, and Osage University Partners. The company said the new funding will go towards its product pipeline and a potential filing for regulatory approval of its lead compound. More information »